Neurogene (NGNE) Payables (2013 - 2026)

Neurogene has reported Payables for 14 years, with the latest figure at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 52.95% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (up 52.95% YoY), and the FY2025 full-year result was $2.0 million, up 46.18% from the prior year.
• Payables for Q1 2026 stood at $4.7 million, up from $2.0 million in the prior quarter.
• The five-year high for Payables was $8.9 million in Q3 2022, with the low at $625000.0 in Q4 2022.
• Historically, Payables has averaged $3.4 million across 5 years, with a median of $2.6 million in 2023.
• Annual changes were most pronounced in 2022 — Payables plunged 91.57% — and 2023, when it surged 315.36%.
• Neurogene's Payables stood at $625000.0 in 2022, then surged by 315.36% to $2.6 million in 2023, then plunged by 48.54% to $1.3 million in 2024, then surged by 46.18% to $2.0 million in 2025, then soared by 139.89% to $4.7 million in 2026.
• The last three Payables figures came in at $4.7 million (Q1 2026), $2.0 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.